Developer docs
API playgroundTry for free, no card

Search company profiles

Cortechs.ai

Full company profile

uuid0000mnv

Namestring
Cortechs.ai
Legal namestring
Cortechs.ai
Websiteurl
cortechs.ai
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Cortechs.ai, founded in 1996 as Cortechs Labs and incorporated in 2002 in San Diego, develops AI-powered quantitative imaging software for radiologists, neurologists, and oncologists. Its flagship platform, NeuroQuant, performs automated brain segmentation and volumetric analysis across MRI, CT, and PET scans using a proprietary Dynamic Atlas technology that supports ages 3-100. Specialized add-on modules address multiple sclerosis (NeuroQuant MS), brain tumors (NeuroQuant Brain Tumor), ARIA monitoring for anti-amyloid Alzheimer's therapies (NeuroQuant Lesion Surveillance), automated head CT analysis (NeuroQuant CT, acquired from ZepMed in October 2025), and PET tracer quantification (NeuroQuant PET, FDA 510(k)-pending). The company's second core product line, OnQ Prostate, applies a patented Restriction Spectrum Imaging (RSI) diffusion MRI method to improve detection and localization of clinically significant prostate cancer.

The company generates revenue through quote-based annual subscription licensing of its software to hospitals and imaging centers, with products compatible with CPT reimbursement codes (0865T, 0866T for brain MRI and 0649T for prostate MRI). Its go-to-market combines direct enterprise sales, embedded OEM integrations with the three dominant imaging vendors (Philips Smart Reading, Siemens Healthineers Digital Marketplace, and Microsoft PowerScribe One on Azure), and regional distribution partners across Benelux, India, Italy, Turkey, the Middle East, Peru, South Korea, and Canada. With over 1,400 hospital and imaging center customers across 44 countries, 2M+ brains scanned, and multiple FDA 510(k) clearances, Cortechs.ai operates a horizontal segmentation strategy spanning neurology, prostate oncology, neuro-oncology, and MS care. The company is venture-backed, having closed an oversubscribed Series C led by VILAS Ventures with participation from Genting Berhad in November 2024, and maintains SOC 2 Type 2 certification for its cloud platform.

Short descriptiontext

Cortechs.ai develops AI-powered quantitative neuroimaging and prostate imaging software for radiologists, neurologists, and oncologists. Its NeuroQuant and OnQ Prostate platforms deliver automated brain and prostate MRI analysis to 1,400+ hospitals and imaging centers across 44 countries via subscription licensing and OEM integrations.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCovington, United States
HQ citystring
Covington
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI neuroimaging software, quantitative brain MRI, volumetric brain analysis, prostate MRI imaging, radiology AI platform
Industry5 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
NAICS code2 codes
  • Software Publishers5132
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing3345
SIC code2 codes
  • Services-Prepackaged Software7372
  • Surgical & Medical Instruments & Apparatus3841
Product category
AI-Powered Radiology Imaging Software
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Software Licensing and Subscriptions
TypeSubscription Recurring
Description

The company generates revenue through software licensing of its NeuroQuant and OnQ Prostate platforms to hospitals and imaging centers. Products are compatible with CPT codes 0865T and 0866T for AI-assisted quantitative brain MRI analysis, supporting reimbursement.

cortechs.ai
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels8 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Pricing details1 tier
1Enterprise licensing for hospitals and imaging centers
ModelSubscriptionBilling cadenceAnnual
Notes

Quote-based pricing; compatible with CPT codes 0865T, 0866T for brain MRI and 0649T for prostate MRI analysis

cortechs.ai
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 8 records shown
1NeuroQuant
Description

Best-in-class brain segmentation and volumetric analysis AI software for neurodegenerative disease detection and monitoring.

cortechs.ai
+7 more records
Core offering1 text field

Cortechs.ai develops and sells cloud-based AI medical imaging software that performs automated brain segmentation, volumetric analysis, and quantitative measurements from MRI, CT, and PET scans. Its NeuroQuant platform supports neurological and oncological assessment (Alzheimer's, MS, epilepsy, TBI, brain tumors, ARIA monitoring), and OnQ Prostate adds FDA-cleared diffusion MRI analysis for prostate cancer detection. The software is licensed to hospitals, imaging centers, radiologists, neurologists, and oncologists and integrates into PACS and OEM imaging systems from Philips, Siemens, and GE.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 19% improvement in radiologist certainty when determining a change in ventricular volume
+3 more records
Product overview1 text field

Cortechs.ai offers a cloud-based AI-powered medical imaging platform primarily focused on neuroimaging and oncology. The core products are NeuroQuant (brain segmentation and volumetric analysis) and OnQ Prostate (prostate MRI with Restriction Spectrum Imaging). NeuroQuant serves as the primary platform with specialized add-on modules including NeuroQuant MS (multiple sclerosis lesion tracking), NeuroQuant Brain Tumor (glioma, metastasis, and meningioma segmentation), NeuroQuant Lesion Surveillance (ARIA monitoring for anti-amyloid therapy), NeuroQuant CT (automated head CT analysis acquired from ZepMed), and NeuroQuant PET (PET tracer quantification, FDA 510(k)-pending). All NeuroQuant modules share the Dynamic Atlas technology for consistent age-accurate segmentation. The company operates on a platform-plus-modules architecture where the core NeuroQuant engine supports specialized clinical applications, while OnQ Prostate represents a distinct product line focused on prostate cancer detection using RSI technology.

Product and service7 records
1NeuroQuant
CategoryCore neuroimaging platform
Description

Best-in-class cloud-based AI software for brain segmentation and volumetric analysis. Segments, quantifies, and compares brain structure volumes for neurodegenerative disease assessment using Dynamic Atlas technology covering ages 3-100. Includes multiple report types (Dementia, MVID, TBA, MSA, Seizure, Pediatrics, Custom, General) and supports Alzheimer's, MS, epilepsy, TBI, and ARIA. Targeted at radiologists, neurologists, and imaging centers.

2NeuroQuant MS
CategoryNeuroimaging add-on module
Description

Specialized module for multiple sclerosis that automatically labels and visualizes MS lesions with color-coded segmentation. Provides longitudinal tracking of new, stable, shrinking, and enlarging lesions and includes a FLAIR Lesion and Atrophy Report with lesion burden and count metrics for treatment planning. For neurologists and radiology departments managing MS patients.

3NeuroQuant Brain Tumor
CategoryNeuroimaging add-on module
Description

FDA-cleared AI software for brain tumor analysis assisting radiologists, oncologists, and neurosurgeons. Provides automated volumetric segmentation and tracking of gliomas (high-grade and low-grade), brain metastases, and meningiomas in pre- and post-operative studies. Generates RT STRUCT outputs for radiation oncology and surgical planning.

4NeuroQuant Lesion Surveillance
CategoryNeuroimaging add-on module
Description

FDA-cleared automated solution for quantification, visualization, and longitudinal tracking of brain lesions. First clinically validated solution identifying cerebral microbleeds and superficial siderosis on T2*GRE and SWI scans, combined with FLAIR lesion quantification. Supports ARIA monitoring for patients on anti-amyloid Alzheimer's therapies with FLAIR and GRE surveillance reports.

5NeuroQuant CT
CategoryNeuroimaging add-on module
Description

FDA-cleared automated post-processing software for head CT scans. Registers CT images to anatomical atlas along the AC-PC plane, quantifies lateral ventricle volume, calculates midline shift index, and generates subtraction maps by co-registering current and prior exams. Acquired from ZepMed (formerly NeuroAlign CT). For emergency departments, radiology, and neurology departments performing head CT.

6NeuroQuant PET
CategoryNeuroimaging add-on module
Description

Rapid automated regional tracer quantification for brain PET images. Provides fully automated quantification of Amyloid, Tau, and FDG PET data with Centiloid quantification for comparison across tracers and time. FDA 510(k)-pending (Research Use Only). Supports PET-MRI, PET-CT, or PET-only workflows. Targets nuclear medicine and dementia-imaging programs.

7OnQ Prostate
CategoryCore prostate imaging product
Description

FDA-cleared prostate MRI software using patented Restriction Spectrum Imaging (RSI) diffusion MRI method. Improves detection, in vivo characterization, and localization of clinically significant prostate cancer. Generates Restricted Signal Maps and Color Fusion Maps for enhanced PI-RADS scoring, biopsy targeting, and treatment planning. For urology practices, radiology departments, and cancer centers.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2026-06-03
Description

Strategic collaboration to integrate AI-powered quantitative imaging biomarkers into clinical radiology workflows through Microsoft's PowerScribe One platform using Azure cloud infrastructure. Embeds NeuroQuant and OnQ Prostate applications into Microsoft's radiology ecosystem.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-27
Description

Partnership to advance AI-driven neuro and prostate imaging in the Middle East region.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-03-04
Description

Partnership to integrate NeuroQuant Lesion Surveillance into Siemens Healthineers Digital Marketplace, enabling clinicians to access automated lesion segmentation, volumetric quantification, and longitudinal tracking within existing radiology workflows.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-11-19
Description

Extended partnership to integrate Cortechs.ai's AI-enabled neuroimaging analytics directly into Philips MR systems through the Smart Reading environment. Provides automated quantitative brain analysis for conditions like Alzheimer's disease, MS, and brain tumors via zero-click workflow.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-07
Description

Expanded partnership to advance imaging innovation across private practices. Alliance now includes Cortechs.ai's full suite of imaging solutions for private radiology practices.

6RMS Medical Devices
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-11
Description

Distribution partnership to expand access to AI-powered neuroimaging solutions in the Benelux region (Belgium, Netherlands, Luxembourg).

cortechs.ai
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-06-04
Description

Strategic partnership to advance AI integration in radiology through deepc's platform capabilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-18
Description

Strategic collaboration to improve Alzheimer's disease care through AI-driven imaging, specifically supporting ARIA monitoring for patients on anti-amyloid therapies.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-27
Description

Distribution partnership to expand AI-driven neuroimaging access in India.

Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-20
Description

Distribution partnership to expand presence in Italy, Turkey, and the Middle East.

11EDAP TMS
Strategic tierRegionalTypeTechnology or IntegrationAnnounced on2025-02-06
Description

World's first OnQ Prostate-assisted Focal One robotic HIFU procedure at UCSF Prostate Cancer Center, demonstrating integration with EDAP's robotic HIFU technology.

cortechs.ai
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-11-25
Description

Partnership to bring precision AI imaging solutions to MRI and CT services.

13Ascend Imaging
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-09-30
Description

Strategic partnership to expand access to cutting-edge radiology solutions.

cortechs.ai
Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Viz.ai builds radiology AI workflow and care-coordination software, primarily known for neurovascular triage but expanding across enterprise imaging; it competes with Cortechs.ai for neuro AI placement within hospital systems.

TypeDirect peer
Description

icometrix provides AI-based brain MRI quantification (e.g., icobrain) for multiple sclerosis, dementia, and similar neurodegenerative use cases, making it a direct, like-for-like competitor to Cortechs.ai's NeuroQuant product line in quantitative neuroimaging.

TypeDirect peer
Description

Aidoc is a leading clinical AI platform offering radiology AI modules across multiple body parts and triage use cases, competing for the same hospital and imaging center AI budgets as Cortechs.ai, although with a broader body-part coverage.

TypeEmerging player
Description

Annalise.ai offers a comprehensive radiology AI suite covering chest, brain, and other body parts; it competes for the same multi-modality imaging AI budgets that hospitals weigh against Cortechs.ai's brain and prostate offerings.

TypeEmerging player
Description

Perspectum develops quantitative imaging biomarkers, with strong presence in liver and brain MR analysis, overlapping with Cortechs.ai's volumetric brain quantification for chronic disease management.

TypeEmerging player
Description

Blackford operates an AI marketplace and integration platform for radiology algorithms, including third-party brain and prostate AI apps; it intersects with Cortechs.ai at the distribution/platform layer rather than as a direct algorithm competitor.

7MIM Software
TypeDirect peer
Description

MIM Software provides medical imaging post-processing and AI-driven quantification across modalities including brain MRI and prostate, sitting in the same clinical and enterprise imaging workflow slots as Cortechs.ai.

TypeEmerging player
Description

Subtle Medical focuses on AI-based image enhancement and acceleration for MRI and PET, sitting adjacent to Cortechs.ai's quantitative analysis products and competing for the same modality-based AI slots in radiology departments.

TypeDirect peer
Description

RapidAI offers AI neuroimaging products (stroke, aneurysm, and now expanded modules), overlapping with Cortechs.ai's NeuroQuant brain volumetric and lesion surveillance offerings for neurology and neuroradiology.

TypeDirect peer
Description

Quibim provides AI-powered medical image analysis across MRI and CT, including quantitative brain imaging biomarkers for neurodegenerative disease, closely mirroring Cortechs.ai's quantitative neuroimaging value proposition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cortechs.ai

AI-Powered Radiology Imaging Softwarecortechs.ai

Cortechs.ai develops AI-powered quantitative neuroimaging and prostate imaging software for radiologists, neurologists, and oncologists. Its NeuroQuant and OnQ Prostate platforms deliver automated brain and prostate MRI analysis to 1,400+ hospitals and imaging centers across 44 countries via subscription licensing and OEM integrations.

What Cortechs.ai does

Cortechs.ai, founded in 1996 as Cortechs Labs and incorporated in 2002 in San Diego, develops AI-powered quantitative imaging software for radiologists, neurologists, and oncologists. Its flagship platform, NeuroQuant, performs automated brain segmentation and volumetric analysis across MRI, CT, and PET scans using a proprietary Dynamic Atlas technology that supports ages 3-100. Specialized add-on modules address multiple sclerosis (NeuroQuant MS), brain tumors (NeuroQuant Brain Tumor), ARIA monitoring for anti-amyloid Alzheimer's therapies (NeuroQuant Lesion Surveillance), automated head CT analysis (NeuroQuant CT, acquired from ZepMed in October 2025), and PET tracer quantification (NeuroQuant PET, FDA 510(k)-pending). The company's second core product line, OnQ Prostate, applies a patented Restriction Spectrum Imaging (RSI) diffusion MRI method to improve detection and localization of clinically significant prostate cancer.

The company generates revenue through quote-based annual subscription licensing of its software to hospitals and imaging centers, with products compatible with CPT reimbursement codes (0865T, 0866T for brain MRI and 0649T for prostate MRI). Its go-to-market combines direct enterprise sales, embedded OEM integrations with the three dominant imaging vendors (Philips Smart Reading, Siemens Healthineers Digital Marketplace, and Microsoft PowerScribe One on Azure), and regional distribution partners across Benelux, India, Italy, Turkey, the Middle East, Peru, South Korea, and Canada. With over 1,400 hospital and imaging center customers across 44 countries, 2M+ brains scanned, and multiple FDA 510(k) clearances, Cortechs.ai operates a horizontal segmentation strategy spanning neurology, prostate oncology, neuro-oncology, and MS care. The company is venture-backed, having closed an oversubscribed Series C led by VILAS Ventures with participation from Genting Berhad in November 2024, and maintains SOC 2 Type 2 certification for its cloud platform.

Cortechs.ai firmographics

Firmographics
Name
Cortechs.ai
Legal name
Cortechs.ai
Website
https://cortechs.ai
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
51–100 employees
Short description
Cortechs.ai develops AI-powered quantitative neuroimaging and prostate imaging software for radiologists, neurologists, and oncologists. Its NeuroQuant and OnQ Prostate platforms deliver automated brain and prostate MRI analysis to 1,400+ hospitals and imaging centers across 44 countries via subscription licensing and OEM integrations.
Ownership category
akta.pro rank

Cortechs.ai industry classification

Industry
Product category
AI-Powered Radiology Imaging Software
NAICS
Software Publishers (5132), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
SIC
Services-Prepackaged Software (7372), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAHABAJ
Radiology AI, CAD & Advanced Visualization Software
Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
SECONDARYHLACALAG
AI Orchestration & Imaging Analytics Platforms (Model Management/Triage)
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

Keywords

  • AI neuroimaging software
  • Quantitative brain MRI
  • Volumetric brain analysis
  • Prostate MRI imaging
  • Radiology AI platform

Where Cortechs.ai is headquartered

Location

Headquarters

HQ city
Covington
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Cortechs.ai business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations

Revenue model

  1. Software Licensing and Subscriptions: The company generates revenue through software licensing of its NeuroQuant and OnQ Prostate platforms to hospitals and imaging centers. Products are compatible with CPT codes 0865T and 0866T for AI-assisted quantitative brain MRI analysis, supporting reimbursement.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualEnterprise licensing for hospitals and imaging centers

Go-to-market motion1 record

Distribution channels8 records

Marketing channels4 records

Cortechs.ai product offering

Product offering

Core offering

Cortechs.ai develops and sells cloud-based AI medical imaging software that performs automated brain segmentation, volumetric analysis, and quantitative measurements from MRI, CT, and PET scans. Its NeuroQuant platform supports neurological and oncological assessment (Alzheimer's, MS, epilepsy, TBI, brain tumors, ARIA monitoring), and OnQ Prostate adds FDA-cleared diffusion MRI analysis for prostate cancer detection. The software is licensed to hospitals, imaging centers, radiologists, neurologists, and oncologists and integrates into PACS and OEM imaging systems from Philips, Siemens, and GE.

Product overview

Cortechs.ai offers a cloud-based AI-powered medical imaging platform primarily focused on neuroimaging and oncology. The core products are NeuroQuant (brain segmentation and volumetric analysis) and OnQ Prostate (prostate MRI with Restriction Spectrum Imaging). NeuroQuant serves as the primary platform with specialized add-on modules including NeuroQuant MS (multiple sclerosis lesion tracking), NeuroQuant Brain Tumor (glioma, metastasis, and meningioma segmentation), NeuroQuant Lesion Surveillance (ARIA monitoring for anti-amyloid therapy), NeuroQuant CT (automated head CT analysis acquired from ZepMed), and NeuroQuant PET (PET tracer quantification, FDA 510(k)-pending). All NeuroQuant modules share the Dynamic Atlas technology for consistent age-accurate segmentation. The company operates on a platform-plus-modules architecture where the core NeuroQuant engine supports specialized clinical applications, while OnQ Prostate represents a distinct product line focused on prostate cancer detection using RSI technology.

Differentiator

Problem solved

Functional benefit

Brands

  • NeuroQuant: Best-in-class brain segmentation and volumetric analysis AI software for neurodegenerative disease detection and monitoring.
  • NeuroQuant MS
  • NeuroQuant Brain Tumor
  • NeuroQuant Lesion Surveillance
  • NeuroQuant CT
  • NeuroQuant PET
  • OnQ Prostate
  • Dynamic Atlas

Products and services

  • NeuroQuant Best-in-class cloud-based AI software for brain segmentation and volumetric analysis. Segments, quantifies, and compares brain structure volumes for neurodegenerative disease assessment using Dynamic Atlas technology covering ages 3-100. Includes multiple report types (Dementia, MVID, TBA, MSA, Seizure, Pediatrics, Custom, General) and supports Alzheimer's, MS, epilepsy, TBI, and ARIA. Targeted at radiologists, neurologists, and imaging centers.
  • NeuroQuant MS Specialized module for multiple sclerosis that automatically labels and visualizes MS lesions with color-coded segmentation. Provides longitudinal tracking of new, stable, shrinking, and enlarging lesions and includes a FLAIR Lesion and Atrophy Report with lesion burden and count metrics for treatment planning. For neurologists and radiology departments managing MS patients.
  • NeuroQuant Brain Tumor FDA-cleared AI software for brain tumor analysis assisting radiologists, oncologists, and neurosurgeons. Provides automated volumetric segmentation and tracking of gliomas (high-grade and low-grade), brain metastases, and meningiomas in pre- and post-operative studies. Generates RT STRUCT outputs for radiation oncology and surgical planning.
  • NeuroQuant Lesion Surveillance FDA-cleared automated solution for quantification, visualization, and longitudinal tracking of brain lesions. First clinically validated solution identifying cerebral microbleeds and superficial siderosis on T2*GRE and SWI scans, combined with FLAIR lesion quantification. Supports ARIA monitoring for patients on anti-amyloid Alzheimer's therapies with FLAIR and GRE surveillance reports.
  • NeuroQuant CT FDA-cleared automated post-processing software for head CT scans. Registers CT images to anatomical atlas along the AC-PC plane, quantifies lateral ventricle volume, calculates midline shift index, and generates subtraction maps by co-registering current and prior exams. Acquired from ZepMed (formerly NeuroAlign CT). For emergency departments, radiology, and neurology departments performing head CT.
  • NeuroQuant PET Rapid automated regional tracer quantification for brain PET images. Provides fully automated quantification of Amyloid, Tau, and FDG PET data with Centiloid quantification for comparison across tracers and time. FDA 510(k)-pending (Research Use Only). Supports PET-MRI, PET-CT, or PET-only workflows. Targets nuclear medicine and dementia-imaging programs.
  • OnQ Prostate FDA-cleared prostate MRI software using patented Restriction Spectrum Imaging (RSI) diffusion MRI method. Improves detection, in vivo characterization, and localization of clinically significant prostate cancer. Generates Restricted Signal Maps and Color Fusion Maps for enhanced PI-RADS scoring, biopsy targeting, and treatment planning. For urology practices, radiology departments, and cancer centers.

Quantifiable outcome

  • 19% improvement in radiologist certainty when determining a change in ventricular volume
  • +3 more outcomes

Companies that use Cortechs.ai

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles1 record

Cortechs.ai technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability5 records

Feature6 records

Cortechs.ai partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and regional.

  • MicrosoftcoreTechnology or Integration · 3 June 2026Strategic collaboration to integrate AI-powered quantitative imaging biomarkers into clinical radiology workflows through Microsoft's PowerScribe One platform using Azure cloud infrastructure. Embeds NeuroQuant and OnQ Prostate applications into Microsoft's radiology ecosystem.
  • ARJ MedicalregionalChannel Partner/ Reseller/ Distributor · 27 May 2026Partnership to advance AI-driven neuro and prostate imaging in the Middle East region.
  • Siemens HealthineerscoreChannel Partner/ Reseller/ Distributor · 4 March 2026Partnership to integrate NeuroQuant Lesion Surveillance into Siemens Healthineers Digital Marketplace, enabling clinicians to access automated lesion segmentation, volumetric quantification, and longitudinal tracking within existing radiology workflows.
  • PhilipscoreTechnology or Integration · 19 November 2025Extended partnership to integrate Cortechs.ai's AI-enabled neuroimaging analytics directly into Philips MR systems through the Smart Reading environment. Provides automated quantitative brain analysis for conditions like Alzheimer's disease, MS, and brain tumors via zero-click workflow.
  • Strategic RadiologycoreStrategic or Co-development Partner · 7 October 2025Expanded partnership to advance imaging innovation across private practices. Alliance now includes Cortechs.ai's full suite of imaging solutions for private radiology practices.
  • RMS Medical DevicesregionalChannel Partner/ Reseller/ Distributor · 11 June 2025Distribution partnership to expand access to AI-powered neuroimaging solutions in the Benelux region (Belgium, Netherlands, Luxembourg).
  • deepccoreTechnology or Integration · 4 June 2025Strategic partnership to advance AI integration in radiology through deepc's platform capabilities.
  • ALZ-NETcoreStrategic or Co-development Partner · 18 May 2025Strategic collaboration to improve Alzheimer's disease care through AI-driven imaging, specifically supporting ARIA monitoring for patients on anti-amyloid therapies.
  • Kryptonite SolutionsregionalChannel Partner/ Reseller/ Distributor · 27 March 2025Distribution partnership to expand AI-driven neuroimaging access in India.
  • Medical HorizonsregionalChannel Partner/ Reseller/ Distributor · 20 March 2025Distribution partnership to expand presence in Italy, Turkey, and the Middle East.
  • EDAP TMSregionalTechnology or Integration · 6 February 2025World's first OnQ Prostate-assisted Focal One robotic HIFU procedure at UCSF Prostate Cancer Center, demonstrating integration with EDAP's robotic HIFU technology.
  • Mermaid Beach RadiologyregionalChannel Partner/ Reseller/ Distributor · 25 November 2024Partnership to bring precision AI imaging solutions to MRI and CT services.
  • Ascend ImagingregionalChannel Partner/ Reseller/ Distributor · 30 September 2024Strategic partnership to expand access to cutting-edge radiology solutions.

Scale indicators9 records

Recent moves10 records

Expansion highlights8 records

Cortechs.ai competitors and assessment

Company assessment

Direct peers

  • Viz.ai: Viz.ai builds radiology AI workflow and care-coordination software, primarily known for neurovascular triage but expanding across enterprise imaging; it competes with Cortechs.ai for neuro AI placement within hospital systems.
  • icometrix: icometrix provides AI-based brain MRI quantification (e.g., icobrain) for multiple sclerosis, dementia, and similar neurodegenerative use cases, making it a direct, like-for-like competitor to Cortechs.ai's NeuroQuant product line in quantitative neuroimaging.
  • Aidoc: Aidoc is a leading clinical AI platform offering radiology AI modules across multiple body parts and triage use cases, competing for the same hospital and imaging center AI budgets as Cortechs.ai, although with a broader body-part coverage.
  • MIM Software: MIM Software provides medical imaging post-processing and AI-driven quantification across modalities including brain MRI and prostate, sitting in the same clinical and enterprise imaging workflow slots as Cortechs.ai.
  • RapidAI: RapidAI offers AI neuroimaging products (stroke, aneurysm, and now expanded modules), overlapping with Cortechs.ai's NeuroQuant brain volumetric and lesion surveillance offerings for neurology and neuroradiology.
  • Quibim: Quibim provides AI-powered medical image analysis across MRI and CT, including quantitative brain imaging biomarkers for neurodegenerative disease, closely mirroring Cortechs.ai's quantitative neuroimaging value proposition.

Emerging players

  • Annalise.ai: Annalise.ai offers a comprehensive radiology AI suite covering chest, brain, and other body parts; it competes for the same multi-modality imaging AI budgets that hospitals weigh against Cortechs.ai's brain and prostate offerings.
  • Perspectum: Perspectum develops quantitative imaging biomarkers, with strong presence in liver and brain MR analysis, overlapping with Cortechs.ai's volumetric brain quantification for chronic disease management.
  • Blackford Analysis: Blackford operates an AI marketplace and integration platform for radiology algorithms, including third-party brain and prostate AI apps; it intersects with Cortechs.ai at the distribution/platform layer rather than as a direct algorithm competitor.
  • Subtle Medical: Subtle Medical focuses on AI-based image enhancement and acceleration for MRI and PET, sitting adjacent to Cortechs.ai's quantitative analysis products and competing for the same modality-based AI slots in radiology departments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Cortechs.ai social profiles

Digital presence

Cortechs.ai compliance and trust

Trust signal

Compliance1 record

Cortechs.ai financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cortechs.ai leadership team

Management profile

Number of profiles

Profiles14 records

Cortechs.ai funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cortechs.ai M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cortechs.ai

What does Cortechs.ai do?

Cortechs.ai develops and sells cloud-based AI medical imaging software that performs automated brain segmentation, volumetric analysis, and quantitative measurements from MRI, CT, and PET scans. Its NeuroQuant platform supports neurological and oncological assessment (Alzheimer's, MS, epilepsy, TBI, brain tumors, ARIA monitoring), and OnQ Prostate adds FDA-cleared diffusion MRI analysis for prostate cancer detection. The software is licensed to hospitals, imaging centers, radiologists, neurologists, and oncologists and integrates into PACS and OEM imaging systems from Philips, Siemens, and GE.

Is Cortechs.ai a public or private company?

Cortechs.ai is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cortechs.ai founded?

Cortechs.ai was founded in 2002. It employs 51 to 100 people.

Where is Cortechs.ai based?

Cortechs.ai is headquartered in Covington, United States, in the North America region.

How does Cortechs.ai make money?

One revenue line is on record: software Licensing and Subscriptions.

Who are Cortechs.ai's main competitors?

Direct peers on record are Viz.ai, icometrix, Aidoc, MIM Software, RapidAI and Quibim. Emerging players are Annalise.ai, Perspectum, Blackford Analysis and Subtle Medical.

Does Cortechs.ai have an API?

No public API is recorded for Cortechs.ai.

What industry is Cortechs.ai in?

Cortechs.ai's product category is AI-Powered Radiology Imaging Software. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Longevity.TechnologyCortechs.ai, Subtle Medical partner to speed MRI measuresCortechs.ai and Subtle Medical announced a strategic partnership on Nov. 10, 2026, to integrate Cortechs.ai's NeuroQuant portfolio with Subtle Medical's MRI enhancement solutions. The partnership combines automated brain volumetry and lesion quantification with AI image enhancement and alignment.PR NewswireCortechs.ai and Subtle Medical Partner to Deliver Faster MRI with Standardized Quantitative NeuroimagingCortechs.ai and Subtle Medical announced a partnership to integrate Cortechs.ai's NeuroQuant neuroimaging portfolio with Subtle Medical's MRI enhancement solutions. The integration aims to support faster imaging protocols and consistent quantitative analysis, with results returned to PACS. The companies will showcase the collaboration at RSNA 2026.Digital Health NewsViz.ai Partners With Cortechs.ai to Expand AI-Powered Neurodegenerative Disease CareViz.ai partnered with Cortechs.ai to integrate NeuroQuant MS quantitative MRI analysis into its Viz Neuro Suite, targeting multiple sclerosis care. The integration aims to provide clinicians with quantitative MRI insights for faster disease progression identification and informed treatment decisions. Viz.ai plans to expand into other neurodegenerative conditions with additional partnerships and product announcements expected soon.Longevity.TechnologyFDA clears software that quantifies amyloid in Alzheimer’sCortechs.ai's NeuroQuant PET software received FDA 510(k) clearance on 18 August for automated amyloid quantification in Alzheimer's PET scans. The software converts tracer uptake into standardized Centiloids, reducing reader variability. The clearance supports earlier detection and precision medicine for amyloid-targeting Alzheimer's treatments.Longevity.TechnologyFDA clears AI software to help analyze brain scans for cognitive declineThe FDA has granted 510(k) clearance to Cortechs.ai for NeuroQuant PET, an AI software designed to assist physicians in evaluating cognitive impairment and neurological conditions via PET scans. The platform provides automated quantification and structured reporting for amyloid PET tracers, integrating into routine clinical workflows. This approval enables the company to deploy its quantitative imaging metrics within existing PACS systems.PR NewswireCortechs.ai Expands European CE Marking Across AI Imaging Platform, Accelerating Global GrowthCortechs.ai expanded its European CE Marking under the EU MDR for its AI imaging products, including NeuroQuant and OnQ Prostate. The certification enables commercialization across the European Economic Area and supports the company's global growth strategy.Longevity.TechnologyViz.ai expands into neurodegenerative disease with Cortechs.aiViz.ai announced a collaboration with Cortechs.ai to integrate NeuroQuant and NeuroQuant MS quantitative neuroimaging tools into the Viz.ai platform, marking Viz.ai's expansion into neurodegenerative disease beyond its existing neuro offerings. The partnership will initially focus on multiple sclerosis, embedding NeuroQuant MS quantitative MRI analysis into Viz.ai's care coordination workflow to help clinicians identify and manage MS patients at scale. Viz.ai currently has an established footprint of nearly 2,000 U.S. hospitals, and additional neurodegenerative disease-focused partnerships and product announcements are expected from Viz.ai in the near future.Imaging Technology NewsViz.ai, Cortechs.ai NeurodegenerativeViz.ai announced a collaboration with Cortechs.ai to integrate the latter's NeuroQuant and NeuroQuant MS neuroimaging analysis tools into the Viz.ai care coordination platform. The partnership marks Viz.ai's expansion into neurodegenerative disease, beginning with multiple sclerosis, and leverages Viz.ai's existing network of nearly 2,000 U.S. hospitals. Cortechs.ai CEO Kyle Frye stated the collaboration exemplifies the vision of connected healthcare AI platforms combining quantitative imaging insights with care coordination infrastructure to improve patient outcomes.ForbesViz.ai And Cortechs.ai Collaborate To Improve MS CareViz.ai and Cortechs.ai announced a partnership on July 9 to integrate Cortechs.ai's NeuroQuant MS brain MRI analysis software into Viz.ai's clinical coordination platform, starting with multiple sclerosis care. The collaboration aims to deliver quantitative lesion burden and brain volume measurements directly to clinicians within existing hospital workflows, addressing the common problem of AI imaging outputs failing to reach the right clinician in time to influence treatment decisions. The partnership reflects Viz.ai's platform strategy of using its footprint of approximately 2,000 U.S. hospitals to integrate external specialized AI technologies rather than developing all capabilities internally.